Wealthstreet Investment Advisors LLC boosted its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 6.0% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 166,957 shares of the biopharmaceutical company’s stock after acquiring an additional 9,500 shares during the period. Bristol-Myers Squibb accounts for 1.1% of Wealthstreet Investment Advisors LLC’s portfolio, making the stock its 22nd largest holding. Wealthstreet Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $7,965,000 as of its most recent filing with the SEC.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Financial Gravity Wealth Inc. purchased a new position in shares of Bristol-Myers Squibb in the 1st quarter worth $26,000. Capital Financial Planning LLC purchased a new position in shares of Bristol-Myers Squibb in the 4th quarter worth $28,000. Well Done LLC bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $30,000. Trust Department MB Financial Bank N A bought a new stake in shares of Bristol-Myers Squibb in the 1st quarter worth about $32,000. Finally, Riverview Trust Co bought a new stake in shares of Bristol-Myers Squibb in the 4th quarter worth about $33,000. 77.65% of the stock is owned by institutional investors.
BMY traded up $0.56 on Wednesday, reaching $47.43. 334,996 shares of the company traded hands, compared to its average volume of 17,793,857. Bristol-Myers Squibb Co has a one year low of $44.30 and a one year high of $63.69. The firm has a market capitalization of $76.47 billion, a price-to-earnings ratio of 11.92, a PEG ratio of 2.19 and a beta of 0.74. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.93 and a quick ratio of 1.79.
Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $1.10 earnings per share for the quarter, beating analysts’ consensus estimates of $1.09 by $0.01. Bristol-Myers Squibb had a net margin of 22.23% and a return on equity of 48.72%. The company had revenue of $5.92 billion during the quarter, compared to analyst estimates of $5.72 billion. During the same quarter last year, the business posted $0.94 EPS. The firm’s revenue for the quarter was up 14.0% on a year-over-year basis. On average, equities analysts anticipate that Bristol-Myers Squibb Co will post 4.18 earnings per share for the current fiscal year.
Several equities research analysts have recently issued reports on the stock. Goldman Sachs Group assumed coverage on shares of Bristol-Myers Squibb in a report on Tuesday, May 28th. They issued a “buy” rating and a $54.00 target price for the company. Argus lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $46.36 target price for the company. in a report on Monday, May 20th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $54.00 target price for the company in a report on Tuesday, May 7th. ValuEngine upgraded shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating in a report on Saturday, May 4th. Finally, JPMorgan Chase & Co. assumed coverage on shares of Bristol-Myers Squibb in a report on Friday, May 3rd. They issued an “overweight” rating and a $62.00 target price for the company. One analyst has rated the stock with a sell rating, nine have assigned a hold rating and nine have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $56.69.
In related news, insider Karen Murphy Santiago sold 3,065 shares of Bristol-Myers Squibb stock in a transaction dated Thursday, May 16th. The shares were sold at an average price of $47.56, for a total transaction of $145,771.40. Following the completion of the sale, the insider now owns 3,066 shares in the company, valued at approximately $145,818.96. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Theodore R. Samuels II acquired 5,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 16th. The shares were bought at an average price of $47.29 per share, with a total value of $236,450.00. Following the acquisition, the director now directly owns 27,000 shares in the company, valued at $1,276,830. The disclosure for this purchase can be found here. Company insiders own 0.12% of the company’s stock.
WARNING: “Bristol-Myers Squibb Co (NYSE:BMY) Shares Bought by Wealthstreet Investment Advisors LLC” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2019/06/12/bristol-myers-squibb-co-nysebmy-shares-bought-by-wealthstreet-investment-advisors-llc.html.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
See Also: Net Asset Value
Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.